The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Nitric Oxide is recognized as a biological marker for many chronic airway diseases. It has
been standardised for clinical use indicating airway inflammation.
In clinical practice, FeNO can aid confirmation of an asthma diagnosis and can indicate the
degree of steroid-responsiveness. This can help guide physician decisions on the initiation
of inhaled corticosteroid (ICS) therapy, or adjustment of ICS therapy.
Therefore, FeNO measurement could be particularly useful to confirm an asthma diagnosis in
patients with non-specific respiratory symptoms (≥ 6 weeks of cough and/or wheezing and/or
chronic dyspnoea) and to assess how likely they are to benefit from corticosteroid treatment.
This study will assess the suitability of FeNO to predict ICS responsiveness in patients with
non-specific respiratory symptoms.
Additionally, we would like to determine the suitability of FeNO as a diagnostic tool for
asthma in comparison to conventional predictors, e.g. spirometry.